00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
19:59 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Stealth, AOBiome propose Hong Kong offerings

Stealth BioTherapeutics Corp. (Newton, Mass.) and AOBiome Therapeutics Inc. (Cambridge, Mass.) each proposed on July 3 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX). Stealth’s lead candidate is elamipretide, a mitochondrial-targeting tetrapeptide that binds...
22:10 , Jul 3, 2018 |  BC Extra  |  Financial News

Stealth, AOBiome propose Hong Kong offerings

Stealth BioTherapeutics Corp. (Newton, Mass.) and AOBiome Therapeutics Inc. (Cambridge, Mass.) each proposed on Tuesday to list on Hong Kong Exchanges and Clearing Ltd. (HKEX). Stealth’s lead candidate is elamipretide, a mitochondrial-targeting tetrapeptide that binds and...
18:35 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

Stealth BioTherapeutics Inc. (Newton, Mass.) raised $100 million June 18 through two convertible note rounds led by Nan Fung Technology's Pivotal Beta and Morningside Ventures, respectively. Also participating were funds associated with Atlantis Investment Management,...
22:08 , Jun 18, 2018 |  BC Extra  |  Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

Stealth BioTherapeutics Inc. (Newton, Mass.) raised $100 million Monday through two convertible note rounds led by Nan Fung Technology's Pivotal Beta. Also participating were funds associated with Atlantis Investment Management, BVCF Management, CMBC Capital Holdings,...
17:01 , Aug 10, 2017 |  BC Week In Review  |  Clinical News

Stealth begins Phase II/III of elamipretide in Barth syndrome

Stealth BioTherapeutics Inc. (Newton, Mass.) began the double-blind, crossover, U.S. Phase II/III TAZPOWER trial to evaluate subcutaneous elamipretide (MTP-131) in ≥12 patients ages ≥12 with genetically confirmed Barth syndrome. Patients will receive 40 mg elamipretide or...
23:57 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Stealth reports Phase II extension trial data of elamipretide in mitochondrial myopathy

Stealth BioTherapeutics Inc. (Newton, Mass.) reported data from 30 patients with primary mitochondrial myopathy in the Phase II MMPOWER-2 extension trial showing that once-daily 40 mg subcutaneous elamipretide (MTP-131) missed the primary endpoint of improving...
21:24 , Nov 15, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous elamipretide: Ph I started

Stealth began the open-label, U.S. Phase I ReCLAIM trial to evaluate 40 mg subcutaneous elamipretide once daily for 12 weeks in about 40 patients ages ≥55. Stealth BioTherapeutics Inc., Newton, Mass.  Product: Subcutaneous elamipretide (MTP-131) (formerly Ocuvia,...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

IV elamipretide: Phase II data

The double-blind, U.S. Phase II MOTION trial in 40 patients ages 60-85 with documented mitochondrial dysfunction showed that a single infusion of 0.25 mg/kg/hour IV elamipretide given over 2 hours improved mitochondrial energy production as...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous elamipretide: Phase II started

Stealth began the double-blind, placebo-controlled, European Phase II PROGRESS-HF trial to evaluate 4 and 40 mg subcutaneous elamipretide once daily for 28 days in about 45 patients. Stealth BioTherapeutics Inc., Newton, Mass.   Product: Subcutaneous...